ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Haisco Pharmaceutical Group, AstraZeneca and Boehringer Ingelheim side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Haisco Pharmaceutical GroupAstraZenecaBoehringer Ingelheim
studies on the registry1594,1972,305
open to participants now5329861
phase 3 studies under way1120028
reach primary completion within a year2116845
programswith a study of their own in two years27119+5 named only45+21 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHaisco Pharmaceutical GroupAstraZenecaBoehringer Ingelheim
Phase 1

Haisco Pharmaceutical Group: 14 of its 27 programs at phase 1

  1. HSK41959phase 1
  2. HSK46256phase 1
  3. HSK46575phase 1
  4. HSK47977phase 1
  5. HSK55879phase 1

and 9 more — sign in to see them all

52%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%
Phase 2

Haisco Pharmaceutical Group: 5 of its 27 programs at phase 2

  1. HSK42360phase 2
  2. HSK47388phase 2
  3. HSK55718phase 2
  4. Cetuximabphase 2
  5. HSK50042phase 2
19%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%
Phase 3

Haisco Pharmaceutical Group: 7 of its 27 programs at phase 3

  1. florensocatibphase 3
  2. HSK44459phase 3
  3. HSK39004phase 3
  4. HSK39297phase 3
  5. anrikefonphase 3

and 2 more — sign in to see them all

26%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%
Approved, new studies

Haisco Pharmaceutical Group: 1 of its 27 programs at approved, new studies

  1. ciprofolapproved, new study
4%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Haisco Pharmaceutical Group9 readouts · 1 phase 3

Haisco Pharmaceutical Group, Nov ’26: 2 programs whose next study reaches primary completion

  1. florensocatibphase 3 · Nov 0 · NCT07915024
  2. HSK55718phase 2 · Nov 0 · NCT07551739

Haisco Pharmaceutical Group, Dec ’26: 3 programs whose next study reaches primary completion

  1. HSK46575phase 1 · Dec 0 · NCT07007910
  2. HSK39297phase 3 · Dec 5 · NCT07616700
  3. HSK47388phase 2 · Dec 20 · NCT07158268
··

Haisco Pharmaceutical Group, Mar ’27: 1 program whose next study reaches primary completion

  1. HSK44459phase 3 · Mar 0 · NCT07623486
··

Haisco Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HSK39004phase 3 · Jun 11 · NCT07658339
  2. cofrogliptinno phase · Jun 30 · NCT07122102
··

Haisco Pharmaceutical Group, Sep ’27: 1 program whose next study reaches primary completion

  1. HSK60002 tabletsphase 1 · Sep 0 · NCT07920809
·
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Haisco Pharmaceutical Group

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Where they overlap

Conditions where at least two of them have programs: 45 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionHaisco Pharmaceutical GroupAstraZenecaBoehringer Ingelheim
Carcinoma, Non-Small-Cell Lungall three · compare here

Haisco Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2all three · compare here

Haisco Pharmaceutical Group in Diabetes Mellitus, Type 2: 4 programs

  1. HSK7653phase 3
  2. Carbon-14phase 1
  3. Ranolazinephase 1
  4. cofrogliptinno phase

Their studies: Haisco Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

Renal Insufficiency, Chronicall three · compare here

Haisco Pharmaceutical Group in Renal Insufficiency, Chronic: 1 program

  1. ciprofolapproved, new study

Their studies: Haisco Pharmaceutical Group’s studies of Renal Insufficiency, Chronic in search

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Boehringer Ingelheim in Renal Insufficiency, Chronic: 3 programs

  1. vicadrostatphase 3
  2. apecotrepphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Renal Insufficiency, Chronic in search

Renal Insufficiencyall three · compare here

Haisco Pharmaceutical Group in Renal Insufficiency: 2 programs

  1. anrikefonphase 3
  2. HSK7653phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Renal Insufficiency in search

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Boehringer Ingelheim in Renal Insufficiency: 1 program

  1. survodutidephase 3

Their studies: Boehringer Ingelheim’s studies of Renal Insufficiency in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Haisco Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 1 program

  1. HSK39004phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Boehringer Ingelheim in Pulmonary Disease, Chronic Obstructive: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Pulmonary Disease, Chronic Obstructive in search

Neoplasmsall three · compare here

Haisco Pharmaceutical Group in Neoplasms: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Boehringer Ingelheim in Neoplasms: 1 program

  1. ezabenlimabphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasms in search

Idiopathic Pulmonary Fibrosisall three · compare here

Haisco Pharmaceutical Group in Idiopathic Pulmonary Fibrosis: 2 programs

  1. HSK44459phase 3
  2. HSK50042phase 2

Their studies: Haisco Pharmaceutical Group’s studies of Idiopathic Pulmonary Fibrosis in search

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Boehringer Ingelheim in Idiopathic Pulmonary Fibrosis: 4 programs

  1. nerandomilastphase 3
  2. BI 3810477phase 2
  3. BI 765423phase 2
  4. BI 1819479phase 2

Their studies: Boehringer Ingelheim’s studies of Idiopathic Pulmonary Fibrosis in search

Colorectal Neoplasmsall three · compare here

Haisco Pharmaceutical Group in Colorectal Neoplasms: 2 programs

  1. HSK42360phase 2
  2. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

Squamous Cell Carcinoma of Head and Neckall three · compare here

Haisco Pharmaceutical Group in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Squamous Cell Carcinoma of Head and Neck in search

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Boehringer Ingelheim in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. ezabenlimabphase 3
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2

Their studies: Boehringer Ingelheim’s studies of Squamous Cell Carcinoma of Head and Neck in search

Bronchiectasisall three · compare here

Haisco Pharmaceutical Group in Bronchiectasis: 1 program

  1. florensocatibphase 3

Their studies: Haisco Pharmaceutical Group’s studies of Bronchiectasis in search

AstraZeneca in Bronchiectasis: 1 program

  1. AZD0292phase 2

Their studies: AstraZeneca’s studies of Bronchiectasis in search

Boehringer Ingelheim in Bronchiectasis: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Bronchiectasis in search

Colitis, Ulcerativeall three · compare here

Haisco Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. HSK47388phase 2

Their studies: Haisco Pharmaceutical Group’s studies of Colitis, Ulcerative in search

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Boehringer Ingelheim in Colitis, Ulcerative: 1 program

  1. BI 3032950phase 2

Their studies: Boehringer Ingelheim’s studies of Colitis, Ulcerative in search

Breast Neoplasms2 of 3 · compare here–

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Boehringer Ingelheim in Breast Neoplasms: 2 programs

  1. zongertinibphase 3
  2. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Breast Neoplasms in search

Show all 45

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Haisco Pharmaceutical Group 7 of 27 · AstraZeneca 68 of 119 · Boehringer Ingelheim 24 of 45 programs (45 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Boehringer Ingelheim: 21).